Rejuvenate Biomed Completes Patient Recruitment for Phase 2 Trial of First-in-Class Sarcopenia Drug RJx-01
核心洞察
Rejuvenate Biomed (搜索) has completed patient recruitment for the MINT-COPD (搜索) Phase 2 trial of RJx-01, targeting muscle wasting in COPD patients with topline data expected by end of 2026.
RJx-01 represents a first-in-class multi-target approach addressing mitochondrial dysfunction (搜索), inflammation (搜索), fibrosis (搜索), and neuromuscular impairment in sarcopenia (搜索) treatment.
The trial addresses a significant unmet medical need, as sarcopenia (搜索) affects 14-67% of COPD (搜索) patients and over 50 million people globally with no approved drug treatments.
Belgian clinical-stage biopharmaceutical company Rejuvenate Biomed (搜索) announced the completion of patient recruitment for its pivotal Phase 2 trial of RJx-01, a first-in-class therapeutic targeting muscle weakness (搜索) and sarcopenia (搜索) in patients with chronic obstructive pulmonary disease (搜索) (COPD (搜索)). The MINT-COPD trial represents a critical milestone in addressing a condition for which no approved drug treatments currently exist, with topline data expected by the end of 2026.
Addressing a Critical Unmet Medical Need
Sarcopenia (搜索) affects more than 50 million people globally and is characterized by progressive loss of physical performance and skeletal muscle strength. In COPD (搜索) patients, the prevalence ranges from 14% to as high as 67%, depending on disease severity and other factors. The condition creates a debilitating cycle where underlying systemic inflammation (搜索) and oxidative stress from COPD contribute to muscle breakdown, reducing physical capacity and discouraging exercise that could help maintain muscle mass.
"Sarcopenia (搜索) is a key contributor to disability and mortality in patients with COPD (搜索), driven by reduced muscle mass, strength and endurance that limits patient mobility and independence," said Neil Greening, MD, PhD, a Consultant Physician at University Hospitals of Leicester and the study's Chief Investigator. "In combination with respiratory symptoms, this loss of functional capacity accelerates overall decline, particularly during hospitalizations associated with acute exacerbations."
The sarcopenia (搜索) treatment market, valued at over $3 billion, currently relies entirely on non-pharmacological interventions like resistance training and nutritional supplements, representing one of the largest unmet needs in geriatric and chronic disease medicine.
Novel Multi-Target Therapeutic Approach
RJx-01 distinguishes itself through a sophisticated, multi-pathway approach that simultaneously addresses several core drivers of muscle decline. Unlike previous unsuccessful attempts that focused on single targets, the drug targets mitochondrial dysfunction (搜索), chronic inflammation (搜索), fibrosis (搜索), and impaired neuromuscular signaling (搜索).
This strategy is supported by promising Phase 1b data in healthy older men with immobilization-induced muscle weakness (搜索)—a model that mimics acute muscle loss during hospitalization. The study demonstrated meaningful improvements in muscle strength, physical function, and fatigue resistance while maintaining an excellent safety profile.
"RJx-01 represents a first-in-class treatment with the potential to meaningfully address the condition and change the treatment landscape for patients," commented Jean-Yves Reginster, MD, PhD, a world-renowned expert in musculoskeletal aging and sarcopenia (搜索) management.
AI-Driven Drug Discovery Platform
The innovation behind RJx-01 extends to its discovery origins through Rejuvenate Biomed (搜索)'s proprietary artificial intelligence platforms, CombinAge® and CelegAge®. These systems analyze vast biological data to identify synergistic drug combinations that tackle the complex, multifactorial nature of age-related diseases, moving beyond traditional single-target paradigms.
This technological approach has attracted significant investment, with the company raising over $22 million and securing backing from life sciences investors including Vesalius Biocapital and Rejuveron Life Sciences.
Strategic Trial Design and Partnerships
The MINT-COPD (搜索) Phase 2 trial (ISRCTN14321370) is a randomized, double-blind, placebo-controlled study that will assess RJx-01's effects on muscle strength, physical function, and muscle fatigue resistance, in addition to safety and tolerability. The trial represents a collaboration between Rejuvenate Biomed (搜索), the University of Leicester, and the NIHR Leicester Biomedical Research Centre (搜索), led by Dr. Neil Greening and Dr. Hamish McAuley.
The study is supported by multimillion-dollar funding from Wellcome Leap (搜索)'s Dynamic Resilience program, co-funded by Temasek Trust. Molecular analyses from preclinical studies and the previous Phase 1b trial support RJx-01's potential disease-modifying mechanism of action.
Clinical and Commercial Implications
"Completing recruitment brings RJx-01 closer to an important clinical and strategic inflection point," said Ann Beliën, PhD, Founder and Chief Executive Officer of Rejuvenate Biomed (搜索). "COPD (搜索)-induced sarcopenia (搜索) represents a clinically meaningful entry point into the broader sarcopenia treatment landscape."
A successful Phase 2 trial would represent a major de-risking event for RJx-01 and validate the company's AI-driven discovery platform. The drug's mechanism has potential relevance across multiple muscle health indications, from preventing muscle loss during post-operative recovery to countering effects of rapid weight loss, positioning it to address the growing need for therapies that extend healthspan by maintaining physical function in aging populations.